Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth - Biologics Market Research

Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth
Decision Resources
June 14, 2006
24 Pages
Pub ID: DECR1305277
US $1,900.00 PDF E-mail From Publisher
Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Current research is focusing on the urgent unmet need for agents that improve survival. Improved responses from treatment regimens that combine targeted biological agents with established chemotherapy, as well as increased drug therapy for early-stage patients who are likely to progress based on potential prognostic markers, have already begun and will continue to create market opportunities and propel steady growth of the CLL market. In this report, we provide an overview of CLL, including its staging, epidemiology, and biological markers. We discuss the current treatments and promising late-stage agents in development for CLL, as well as the market outlook though 2010.